Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials

D. Halpin, K. Viel, I. Leimer, L. Grönke (Exeter, United Kingdom; Ingelheim, Germany; Ridgefield, United States Of America)

Source: Annual Congress 2006 - COPD exacerbations
Session: COPD exacerbations
Session type: Poster Discussion
Number: 1074
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Halpin, K. Viel, I. Leimer, L. Grönke (Exeter, United Kingdom; Ingelheim, Germany; Ridgefield, United States Of America). Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials. Eur Respir J 2006; 28: Suppl. 50, 1074

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013



Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


COPD patients with asthma, characteristics and risk of exacerbations
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013



Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015

Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Clinical characteristics of patients with frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS)
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016


Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


The impact of bronchiectasis on outcomes in a large cohort of patients hospitalised with exacerbations of COPD
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013

QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Severe outcomes of COVID-19 among patients with COPD and asthma
Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020
Year: 2021



An evaluation of exacerbations in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 89s
Year: 2004

Clinical and functional effectiveness of roflumilast in severe COPD patients
Source: Annual Congress 2013 –Modern approach to various clinical settings
Year: 2013


Statins and outcome of COPD patients after hospitalization for COPD exacerbations
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010